Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H14O4 |
Molecular Weight | 222.2372 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)\C=C\C1=CC=C(O)C(OC)=C1
InChI
InChIKey=ATJVZXXHKSYELS-FNORWQNLSA-N
InChI=1S/C12H14O4/c1-3-16-12(14)7-5-9-4-6-10(13)11(8-9)15-2/h4-8,13H,3H2,1-2H3/b7-5+
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/15345140Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22324721 | https://www.ncbi.nlm.nih.gov/pubmed/24941338 | https://www.ncbi.nlm.nih.gov/pubmed/27711798 | https://www.ncbi.nlm.nih.gov/pubmed/15826020 | https://goo.gl/QGmZUK
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15345140
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22324721 | https://www.ncbi.nlm.nih.gov/pubmed/24941338 | https://www.ncbi.nlm.nih.gov/pubmed/27711798 | https://www.ncbi.nlm.nih.gov/pubmed/15826020 | https://goo.gl/QGmZUK
Ethyl Ferulate is an ester type of Ferulic Acid and has powerful antioxidant, free radical scavenging and UV adsorption properties. Ethyl Ferulate can be incorporated into various cosmetic formulations including aqueous, ethanolic and emulsion-based creams, sun creams or moisturizers. Ethyl ferulate demonstrated the cytoprotective effects against oxidative damage in neuronal cells. Ethyl ferulate has also been widely studied and some recent findings include its anticholinesterase activity; inhibition of nuclear factor-kappa B (NF-κB) activity in LPS-stimulated RAW 264.7 macrophages; inhibition of inducible nitric oxide synthase (iNOS) induction in UV-induced oxidative stress in melanocytes; induction of heme oxygenase (HO-1) activity in rat astrocytes and neurons, which is a putative pathway against oxidative stress that underline neurodegenerative diseases; and cytoprotective effect against reactive oxygen species (ROS)-induced damage through the stimulation of dermal fibroblasts stress response.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2039 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19321235 |
6.7 µM [IC50] | ||
Target ID: CHEMBL2424 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21237663 |
385.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26497184
Rats were treated with 50 and 100 mg/kg, po as a single dose.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15345140
Rat type 1 astrocytes and rat hippocampal neurons were used for activity evaluation. Cells were grown in 75-cm2 flasks and maintained at 37C in a humidified atmosphere of air and 5% CO2. Confluent cells were exposed to various concentrations of EFE (Ethyl Ferulate) and RSV (trans-3,2,5-trihydrostilbene). After each treatment (6 or 24 h), cells were harvested for the determination of HO activity, HO-1 and HO-2 mRNA levels, and protein expression. Neurons growing in 24 wells were also exposed to different concentrations of EFE, and cell viability was determined at 24 h. Other neurons were pretreated for 12 h with 5 µM EFE or 5 µM EFE plus 10 µM ZnPP IX and then exposed for 2 h to 50 mU/mL GOX, before cell viability was determined.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C275
Created by
admin on Fri Dec 15 16:08:41 GMT 2023 , Edited by admin on Fri Dec 15 16:08:41 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
223-745-5
Created by
admin on Fri Dec 15 16:08:41 GMT 2023 , Edited by admin on Fri Dec 15 16:08:41 GMT 2023
|
PRIMARY | |||
|
C83699
Created by
admin on Fri Dec 15 16:08:41 GMT 2023 , Edited by admin on Fri Dec 15 16:08:41 GMT 2023
|
PRIMARY | |||
|
1420983
Created by
admin on Fri Dec 15 16:08:41 GMT 2023 , Edited by admin on Fri Dec 15 16:08:41 GMT 2023
|
PRIMARY | RxNorm | ||
|
14879
Created by
admin on Fri Dec 15 16:08:41 GMT 2023 , Edited by admin on Fri Dec 15 16:08:41 GMT 2023
|
PRIMARY | |||
|
C099085
Created by
admin on Fri Dec 15 16:08:41 GMT 2023 , Edited by admin on Fri Dec 15 16:08:41 GMT 2023
|
PRIMARY | |||
|
DB11285
Created by
admin on Fri Dec 15 16:08:41 GMT 2023 , Edited by admin on Fri Dec 15 16:08:41 GMT 2023
|
PRIMARY | |||
|
5B8915UELW
Created by
admin on Fri Dec 15 16:08:41 GMT 2023 , Edited by admin on Fri Dec 15 16:08:41 GMT 2023
|
PRIMARY | |||
|
5B8915UELW
Created by
admin on Fri Dec 15 16:08:41 GMT 2023 , Edited by admin on Fri Dec 15 16:08:41 GMT 2023
|
PRIMARY | |||
|
DTXSID001021502
Created by
admin on Fri Dec 15 16:08:41 GMT 2023 , Edited by admin on Fri Dec 15 16:08:41 GMT 2023
|
PRIMARY | |||
|
736681
Created by
admin on Fri Dec 15 16:08:41 GMT 2023 , Edited by admin on Fri Dec 15 16:08:41 GMT 2023
|
PRIMARY | |||
|
4046-02-0
Created by
admin on Fri Dec 15 16:08:41 GMT 2023 , Edited by admin on Fri Dec 15 16:08:41 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD